ストックスクリーナーアプリを入手
3.22
0.62%
-0.02
前日終値:
$3.24
開ける：
$3.23
24時間の取引高:
420.86K
Relative Volume:
0.54
時価総額：
$616.72M
収益：
$12.99M
当期純損益:
$-74.39M
株価収益率:
-7.3182
EPS:
-0.44
ネットキャッシュフロー:
$-78.92M
1週間 パフォーマンス:
+2.88%
1か月 パフォーマンス:
-3.59%
6か月 パフォーマンス:
-3.01%
1年 パフォーマンス:
-17.86%
1日の値動き範囲:
$3.195
$3.26
1週間の範囲:
$3.11
$3.30
52週間の値動き範囲:
$2.705
$4.725
Arbutus Biopharma Corp Stock (ABUS) Company Profile
名前
Arbutus Biopharma Corp
セクター
電話
604-419-3200
住所
701 VETERANS CIRCLE, WARMINSTER, PA
ABUS を他の銘柄と比較する
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
ABUS
Arbutus Biopharma Corp
|
3.22 | 620.55M | 12.99M | -74.39M | -78.92M | -0.44 |
|
VRTX
Vertex Pharmaceuticals Inc
|
469.65 | 121.28B | 11.10B | -988.90M | -1.26B | -3.92 |
|
REGN
Regeneron Pharmaceuticals Inc
|
563.10 | 60.96B | 14.09B | 4.50B | 2.96B | 39.28 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
328.81 | 42.77B | 2.35B | -269.70M | -75.39M | -2.09 |
|
ARGX
Argen X Se Adr
|
591.99 | 36.21B | 2.58B | 1.06B | -1.28B | 16.33 |
|
ONC
Beone Medicines Ltd Adr
|
291.47 | 32.08B | 3.81B | -644.79M | -669.77M | -6.24 |
Arbutus Biopharma Corp Stock (ABUS) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2022-02-02 | アップグレード | Jefferies | Hold → Buy |
| 2021-02-25 | 開始されました | Jefferies | Hold |
| 2020-12-17 | 開始されました | H.C. Wainwright | Buy |
| 2020-07-27 | 再開されました | JMP Securities | Mkt Outperform |
| 2020-07-24 | ダウングレード | Robert W. Baird | Outperform → Neutral |
| 2020-05-19 | アップグレード | Wedbush | Neutral → Outperform |
| 2020-03-06 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2020-02-20 | 開始されました | Robert W. Baird | Outperform |
| 2020-02-05 | アップグレード | JMP Securities | Mkt Perform → Mkt Outperform |
| 2019-10-07 | 繰り返されました | B. Riley FBR | Buy |
| 2019-10-04 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2018-10-16 | アップグレード | B. Riley FBR | Neutral → Buy |
| 2018-10-15 | アップグレード | Wedbush | Underperform → Neutral |
| 2018-10-12 | 繰り返されました | Chardan Capital Markets | Buy |
| 2018-07-06 | ダウングレード | B. Riley FBR, Inc. | Buy → Neutral |
| 2018-03-19 | 再開されました | Chardan Capital Markets | Buy |
| 2018-03-19 | ダウングレード | Wedbush | Outperform → Neutral |
| 2018-01-05 | 開始されました | B. Riley FBR, Inc. | Buy |
| 2017-04-04 | アップグレード | Chardan Capital Markets | Neutral → Buy |
| 2017-02-01 | 繰り返されました | Wedbush | Outperform |
| 2016-12-13 | ダウングレード | Chardan Capital Markets | Buy → Neutral |
| 2016-11-30 | アップグレード | Chardan Capital Markets | Neutral → Buy |
すべてを表示
Arbutus Biopharma Corp (ABUS) 最新ニュース
Is Arbutus Biopharma Corporation a good long term investmentMassive wealth growth - PrintWeekIndia
What analysts say about Arbutus Biopharma Corporation stockSuperior returns - jammulinksnews.com
Arbutus Biopharma Corporation (NASDAQ:ABUS) Position Cut by Teacher Retirement System of Texas - Defense World
What drives Arbutus Biopharma Corporation stock priceSuperior stock growth - Autocar Professional
Arbutus Biopharma Corporation Stock Analysis and ForecastDynamic profit opportunities - jammulinksnews.com
What risks could impact Arbutus Biopharma Corporation stock performanceWealth Building Stock Portfolio - beatles.ru
Why Arbutus Biopharma Corporation stock attracts strong analyst attentionBreakout Confirmation Tool - Newser
What makes Arbutus Biopharma Corporation stock price move sharplyFree Deep Market Trend Analysis - Newser
How Arbutus Biopharma Corporation stock performs during market volatilityFree Daily Stock Market Updates - Newser
Warminster Biopharma Firm Ends $285M Licensing Deal with Chinese Company - BUCKSCO.Today
Arbutus Biopharma (ABUS) Reacquires China Rights to Lead Drug | - GuruFocus
Arbutus Reacquires Greater China Rights to Imdusiran and - GlobeNewswire
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Sold by UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC - Defense World
Ameriprise Financial Inc. Makes New $62,000 Investment in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Bank of America Corp DE Acquires 171,906 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Millennium Management LLC Purchases 92,068 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Deutsche Bank AG Buys 75,212 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Northern Trust Corp Has $4.35 Million Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Reports Q1 2025 Results, Clinical Developments, and Legal Progress - MyChesCo
Mercer Global Advisors Inc. ADV Makes New Investment in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Co. (NASDAQ:ABUS) Stake Boosted by Price T Rowe Associates Inc. MD - Defense World
Arbutus: Q1 Earnings Snapshot - CT Insider
Arbutus Biopharma Corp Reports Q1 2025 Earnings: Revenue at $1.8 Million, EPS Misses Estimate with $0.13 Loss - GuruFocus
Arbutus Biopharma earnings missed by $0.03, revenue fell short of estimates - Investing.com Canada
Arbutus Biopharma (ABUS) Reports Mixed Q1 Results - GuruFocus
Arbutus Biopharma (ABUS) Reports Q1 Loss, Tops Revenue Estimates - Yahoo Finance
Arbutus (ABUS) Reports Lower Q1 Revenue Amid Promising Treatment Progress | ABUS Stock News - GuruFocus
Arbutus Reports First Quarter 2025 Financial Results and Provides Corporate Update - GlobeNewswire
Is Editas Medicine (EDIT) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Arbutus Biopharma Showcases Promising Results for Hepatitis B Therapies at EASL Congress 2025 - MyChesCo
Wells Fargo & Company MN Acquires 21,768 Shares of Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma (ABUS) Showcases Promising Data on Imdusiran and AB-101 | ABUS Stock News - GuruFocus
Arbutus Presents Clinical Trial Data from its Two HBV Assets, Imdusiran and AB-101, at the European Association for the Study of the Liver (EASL) Congress 2025 - GlobeNewswire
Arbutus Presents Clinical Trial Data from its Two HBV - GlobeNewswire
Arbutus Biopharma Co. (NASDAQ:ABUS) Shares Purchased by Barclays PLC - Defense World
Invesco Ltd. Grows Position in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corp (ABUS) is a good investment, but the stock may be overvalued - uspostnews.com
Arbutus Biopharma Corp (ABUS) With A Potential Upside Of More Than -139.44% - Stocksregister
Arbutus Biopharma Corp (ABUS) looking to reclaim success with recent performance - Sete News
Legal & General Group Plc Has $388,000 Stock Holdings in Arbutus Biopharma Co. (NASDAQ:ABUS) - Defense World
Arbutus Biopharma Corp [ABUS] Insider Activity: An Update for Investors - knoxdaily.com
Arbutus Biopharma Corp expected to post a loss of 10 cents a shareEarnings Preview - TradingView
Stock Market Recap: Arbutus Biopharma Corp (ABUS) Concludes at 3.12, a -1.58 Surge/Decline - DWinneX
Is Boston Scientific (BSX) Stock Outpacing Its Medical Peers This Year? - Yahoo Finance
Will Arbutus Biopharma (ABUS) Report Negative Q1 Earnings? What You Should Know - Yahoo Finance
Arbutus Biopharma Showcases Promising Hepatitis B Research at EASL Congress - MyChesCo
Arbutus Biopharma Corp (ABUS)’s stock price in review: A technical analysis - uspostnews.com
Arbutus to Present Imdusiran and AB-101 Data at EASL Congress 2025 - GlobeNewswire
Arbutus Biopharma Corp (ABUS) 財務データ
収益
当期純利益
現金流量
EPS
0.97%
0.22%
大文字化:
|
ボリューム (24 時間):